Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug;15(8):678-90.
doi: 10.1177/1098612X12473994. Epub 2013 Jan 24.

Evaluation of the clinical use of tepoxalin and meloxicam in cats

Anna N Charlton  1 , Javier Benito, Wendy Simpson, Mila Freire, B Duncan X Lascelles
Affiliations

Evaluation of the clinical use of tepoxalin and meloxicam in cats

Anna N Charlton et al. J Feline Med Surg. 2013 Aug.

Abstract

Medical records where tepoxalin (Zubrin) or meloxicam (Metacam) were prescribed in cats were reviewed and data extracted. Comparisons were performed for exploring changes between pre- and post-non-steroidal anti-inflammatory drug course laboratory tests. Seventy-nine medical records fit the inclusion criteria (n = 57 and n = 22, tepoxalin and meloxicam, respectively). The median dosages administered were 13 and 0.029 mg/kg(/)day (tepoxalin and meloxicam, respectively). Median prescription durations were 11 (2-919) and 93 (4-1814) days for tepoxalin and meloxicam, respectively. Suspected adverse events were reported for tepoxalin (9%, 5/57 cats) and meloxicam (18%, 4/22 cats) a median of 774 and 448 days, respectively, after the prescription started. For cats prescribed meloxicam, there were several statistically significant changes for serum biochemistry and hematology parameters, but median values were within normal limits. These valuable clinical data suggest that tepoxalin and meloxicam are well tolerated in the clinical setting at the doses prescribed in this study.

PubMed Disclaimer

Conflict of interest statement

BDXL has received research funding from both Schering-Plough (now Merck Animal Health) and Boehringer-Ingelheim. BDXL has also acted as a consult for both companies and received honoraria for continuing education lectures.

Similar articles

See all similar articles

Cited by

References

    1. Sparkes AH, Heiene R, Lascelles BD, Malik R, Sampietro LR, Robertson S, et al.. ISFM and AAFP consensus guidelines: long-term use of NSAIDs in cats. J Feline Med Surg 2010; 12: 521–538. - PMC - PubMed
    1. DiBernardi L, Dore M, Davis JA, Owens JG, Mohammed SI, Guptill CF, et al.. Study of feline oral squamous cell carcinoma: potential target for cyclooxygenase inhibitor treatment. Prostaglandins Leukot Essent Fatty Acids 2007; 76: 245–250. - PubMed
    1. Hayes A, Scase T, Miller J, Murphy S, Sparkes A, Adams V. COX-1 and COX-2 expression in feline oral squamous cell carcinoma. J Comp Pathol 2006; 135: 93–99. - PubMed
    1. Hayes AM, Adams VJ, Scase TJ, Murphy S. Survival of 54 cats with oral squamous cell carcinoma in United Kingdom general practice. J Small Anim Pract. 2007; 48: 394–399. - PubMed
    1. Bommer NX, Hayes AM, Scase TJ, Gunn-Moore D. Clinical features, survival times and COX-1 and COX-2 expression in cats with transitional cell carcinoma of the urinary bladder treated with meloxicam. J Feline Med Surg 2012; 14: 527–533. - PMC - PubMed

Publication types

LinkOut - more resources